290 related articles for article (PubMed ID: 19137771)
1. Treatment of severe facial psoriasis with adalimumab.
Noiles K; Vender R
J Drugs Dermatol; 2008 Dec; 7(12):1165-7. PubMed ID: 19137771
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
Bagel J
J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
[TBL] [Abstract][Full Text] [Related]
4. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
Noda S; Mizuno K; Adachi M
J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
[TBL] [Abstract][Full Text] [Related]
7. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
Ardigò M; Giuliani A; de Felice C; Mastroianni A; Berardesca E
J Drugs Dermatol; 2008 Oct; 7(10):935-9. PubMed ID: 19112756
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
[TBL] [Abstract][Full Text] [Related]
11. Treatment of psoriasis with adalimumab.
Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
[TBL] [Abstract][Full Text] [Related]
12. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
[TBL] [Abstract][Full Text] [Related]
13. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
[TBL] [Abstract][Full Text] [Related]
14. Treatment of nail psoriasis with adalimumab: an open label unblinded study.
Rigopoulos D; Gregoriou S; Lazaridou E; Belyayeva E; Apalla Z; Makris M; Katsambas A; Ioannides D
J Eur Acad Dermatol Venereol; 2010 May; 24(5):530-4. PubMed ID: 19807825
[TBL] [Abstract][Full Text] [Related]
15. Recalcitrant pustular psoriasis successfully treated with adalimumab.
Alvarez AC; Rodríguez-Nevado I; De Argila D; Rubio FP; Rovira I; Torrelo A; Zambrano A
Pediatr Dermatol; 2011; 28(2):195-7. PubMed ID: 21504452
[TBL] [Abstract][Full Text] [Related]
16. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
[TBL] [Abstract][Full Text] [Related]
17. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
Strober BE; Sobell JM; Duffin KC; Bao Y; Guérin A; Yang H; Goldblum O; Okun MM; Mulani PM
Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
[TBL] [Abstract][Full Text] [Related]
18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
19. Classification of facial psoriasis based on the distributions of facial lesions.
Woo SM; Choi JW; Yoon HS; Jo SJ; Youn JI
J Am Acad Dermatol; 2008 Jun; 58(6):959-63. PubMed ID: 18359126
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
